Researchers sought to analyze the occurrence and severity of cytokine release syndrome in patients with relapsed/refractory multiple myeloma who recieve CAR-T therapy.
Neurotoxicity is common with CAR-T, occurring in 43% of patients in this multicenter, longitudinal study.
Nearly half of all relapses occurred within the first month of CAR-T infusion.
Investigators aimed to determine and compare outcomes in patients with relapsed or refractory ALL who were treated with anti-CD19 CAR T-cell therapy.
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.
Sustained remission of CLL is associated with enrichment of a less-differentiated, early-memory phenotype of T cells in the apheresis product used to make CAR-T therapies.
The occurrence, severity, and need for treatment of cytokine release syndrome were key parameters in the assessment of CAR-T–related neurotoxicity risk.
The NCCN recently released 2 sets of Guidelines for Patients that explain the side effects of different types of immunotherapies, such as CAR T-cell therapies.
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.
The data reinforce the need for direct comparison of CAR-T and autologous transplantation.
